CD262 (DR5) Monoclonal Antibody (DJR2-4 (7-8)), Biotin, eBioscience™, Invitrogen™

Description

• Description: The DJR2-4 monoclonal antibody reacts with human DR5, also known as TRAIL-R2, Apo2, TRICK2 and KILLER
• DR5 binds to TRAIL, activates NF-kappaB, and induces TRAIL-mediated apoptosis
• DR5 is expressed broadly by normal tissues as well as several tumor cells
• Applications Reported: The DJR2-4 (a.k.a
• 7-8) antibody has been reported for use in flow cytometric analysis
• Applications Tested: The DJR2-4 (a.k.a
• 7-8) antibody has been tested by flow cytometric analysis of human MOLT-4 cell line and human DR5-transfected cells
• This can be used at less than or equal to 0.5 μg per test
• A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL
• Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test
• It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest
• Filtration: 0.2 μm post-manufacturing filtered
• DR5 (Apo2, TRAIL-R2, TRICK2, KILLER) is a recently identified death domain containing receptor for TRAIL, which mediates TRAIL induced apoptosis
• DR5 is a member of the TNF-receptor superfamily, and contains an intracellular death domain
• DR5 can be activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL/APO-2L), and transduces an apoptosis signal
• Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by DR5
• Two transcript variants encoding different isoforms of DR5 and one non-coding transcript have been found
• Overexpression of DR5 induces apoptosis and activates NF-kappa-B
• DR5 is expressed in a number of cell types, and to particularly high levels in lymphocytes and spleen
• Diseases associated with DR5 dysfunction include squamous cell carcinoma, and diffuse infiltrative lymphocytosis syndrome.